CN1441676B - 用配体-免疫原缀合物治疗的方法 - Google Patents

用配体-免疫原缀合物治疗的方法 Download PDF

Info

Publication number
CN1441676B
CN1441676B CN018101852A CN01810185A CN1441676B CN 1441676 B CN1441676 B CN 1441676B CN 018101852 A CN018101852 A CN 018101852A CN 01810185 A CN01810185 A CN 01810185A CN 1441676 B CN1441676 B CN 1441676B
Authority
CN
China
Prior art keywords
application
folic acid
ligand
cells
immunogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN018101852A
Other languages
English (en)
Chinese (zh)
Other versions
CN1441676A (zh
Inventor
P·S·罗
Y·卢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of CN1441676A publication Critical patent/CN1441676A/zh
Application granted granted Critical
Publication of CN1441676B publication Critical patent/CN1441676B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN018101852A 2000-03-31 2001-03-30 用配体-免疫原缀合物治疗的方法 Expired - Fee Related CN1441676B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19394400P 2000-03-31 2000-03-31
US60/193,944 2000-03-31
US25584600P 2000-12-15 2000-12-15
US60/255,846 2000-12-15
PCT/US2001/010254 WO2001074382A1 (en) 2000-03-31 2001-03-30 Method of treatment using ligand-immunogen conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012102411983A Division CN102805868A (zh) 2000-03-31 2001-03-30 用配体-免疫原缀合物治疗的方法

Publications (2)

Publication Number Publication Date
CN1441676A CN1441676A (zh) 2003-09-10
CN1441676B true CN1441676B (zh) 2012-08-22

Family

ID=26889531

Family Applications (2)

Application Number Title Priority Date Filing Date
CN018101852A Expired - Fee Related CN1441676B (zh) 2000-03-31 2001-03-30 用配体-免疫原缀合物治疗的方法
CN2012102411983A Pending CN102805868A (zh) 2000-03-31 2001-03-30 用配体-免疫原缀合物治疗的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012102411983A Pending CN102805868A (zh) 2000-03-31 2001-03-30 用配体-免疫原缀合物治疗的方法

Country Status (20)

Country Link
US (2) US7033594B2 (enExample)
EP (1) EP1267918A4 (enExample)
JP (2) JP5059271B2 (enExample)
KR (1) KR100863632B1 (enExample)
CN (2) CN1441676B (enExample)
AU (2) AU2001256970C1 (enExample)
BR (1) BR0109704A (enExample)
CA (1) CA2405299C (enExample)
CZ (1) CZ304942B6 (enExample)
DZ (1) DZ3332A1 (enExample)
EA (1) EA005823B1 (enExample)
HR (1) HRP20020787B1 (enExample)
HU (1) HUP0300421A2 (enExample)
IL (2) IL151927A0 (enExample)
MX (1) MXPA02009454A (enExample)
NO (1) NO332160B1 (enExample)
NZ (1) NZ521898A (enExample)
PL (1) PL211872B1 (enExample)
SK (1) SK288201B6 (enExample)
WO (1) WO2001074382A1 (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US7645743B2 (en) * 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
CA2328356A1 (en) * 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
AU2001256970C1 (en) * 2000-03-31 2008-07-03 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
EP1389209B1 (en) * 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
RU2316349C2 (ru) 2001-05-02 2008-02-10 Пердью Рисерч Фаундейшн Лечение и диагностика заболеваний, опосредованных макрофагами
CA2461877A1 (en) * 2001-09-28 2003-04-10 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
JP5021152B2 (ja) * 2001-10-22 2012-09-05 ザ スクリプス リサーチ インスティチュート インテグリンターゲッティング化合物
US8043603B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
CN1662251B (zh) * 2002-04-19 2012-10-10 恩多塞特公司 佐剂增强的免疫应用
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
WO2003094859A2 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
US7910594B2 (en) * 2002-05-15 2011-03-22 Endocyte, Inc. Vitamin-mitomycin conjugates
AR042942A1 (es) * 2003-01-27 2005-07-06 Endocyte Inc Conjugados de administracion de drogas de union de receptores de vitaminas
CA2514270A1 (en) 2003-02-06 2004-08-19 Tripep Ab Antigen/antibody or ligand/receptor glycosylated specificity exchangers
JP2006524693A (ja) * 2003-04-11 2006-11-02 メディミューン，インコーポレーテッド ＥｐｈＡ２および非腫瘍性過増殖性細胞障害
WO2004100983A2 (en) * 2003-05-06 2004-11-25 Purdue Research Foundation, Inc. Treatment of lupus targeting the macrophages or the folate receptor
ATE412897T1 (de) 2003-05-30 2008-11-15 Purdue Research Foundation Diagnoseverfahren für atherosklerose
US7601511B2 (en) * 2003-11-12 2009-10-13 University Of Georgia Research Foundation, Inc. Biotin-facilitated transport in gram negative bacteria
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
CN1976946A (zh) * 2004-07-03 2007-06-06 财团法人牧岩生命工学研究所 诱导抗hcv有效ctl应答的超型表位、其编码寡核苷酸及其应用
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
CN101128152A (zh) * 2004-12-23 2008-02-20 普渡研究基金会 发射正电子段层成像方法
CN101175757B (zh) * 2005-03-16 2012-11-14 恩多塞特公司 蝶酸及其缀合物的合成和纯化
EP1864133B1 (en) * 2005-03-30 2010-03-10 Purdue Research Foundation Method for breastcancer prognosis using cellular folate vitamin receptor quantification
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
WO2007022493A2 (en) * 2005-08-19 2007-02-22 Endocyte, Inc. Ligand conjugates of vinca alkaloids, analogs, and derivatives
CN103893778A (zh) * 2005-08-19 2014-07-02 恩多塞特公司 多药物配体缀合物
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
EP1951740B1 (en) * 2005-11-10 2014-07-16 James Paulson High affinity siglec ligands
US8168164B2 (en) * 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
US20100226967A1 (en) * 2006-05-23 2010-09-09 Purdue Research Foundation Imaging and therapeutic method using progenitor cells
WO2007143561A1 (en) * 2006-06-01 2007-12-13 Mayo Foundation For Medical Education And Research Immunity to folate receptors
CA2668197A1 (en) 2006-11-03 2008-05-15 Philip S. Low Ex vivo flow cytometry method and device
EP2567711A3 (en) * 2007-02-07 2013-05-01 Purdue Research Foundation Positron emission tomography imaging method
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
JP5829793B2 (ja) * 2007-03-14 2015-12-09 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 結合性リガンドが結合したツブリシンの薬剤送達結合体
US8961926B2 (en) * 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
PT2187965T (pt) 2007-08-17 2020-01-17 Purdue Research Foundation Conjugados ligando-ligante de ligação a psma e métodos para utilização
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
CN101909441B (zh) 2007-10-25 2015-05-13 恩多塞特公司 微管蛋白抑制剂及其制备方法
EP2222328A4 (en) * 2007-11-15 2013-06-05 Endocyte Inc PROCESS FOR THE ADMINISTRATION OF CONJUGATES
JP5746615B2 (ja) 2008-05-13 2015-07-08 エール ユニヴァーシティ 癌細胞への抗体の動員のためのキメラ小分子
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
CN102459298A (zh) * 2009-05-05 2012-05-16 阿尔特姆恩科技责任有限公司 化学可编程免疫
TWI796132B (zh) 2010-02-24 2023-03-11 美商免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
HRP20180358T1 (hr) 2011-04-01 2018-04-06 Immunogen, Inc. Postupci povećavanja djelotvornosti terapije raka usmjerene protiv folr1
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US9629918B2 (en) 2012-02-29 2017-04-25 Purdue Research Foundation Folate receptor alpha binding ligands
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9200073B2 (en) 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
EP2908818A4 (en) 2012-10-16 2016-07-13 Endocyte Inc CONJUGATES OF DRUG DELIVERY CONTAINING ARTIFICIAL AMINO ACIDS AND METHODS OF USE
US9636413B2 (en) 2012-11-15 2017-05-02 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
BR112015022810B1 (pt) 2013-03-15 2021-11-30 Purdue Research Foundation Composto, composição e método para identificar tipo de célula alvo em amostra biológica
US20170232119A1 (en) 2013-03-15 2017-08-17 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
ES2883191T3 (es) 2013-08-30 2021-12-07 Immunogen Inc Anticuerpos y ensayos para la detección del receptor 1 de folato
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP4541378A3 (en) 2013-11-14 2025-07-30 Endocyte, Inc. Compounds for positron emission tomography
GB201411150D0 (en) 2014-06-23 2014-08-06 Altermune Technologies Llc Novel aptamers and therapeutic uses thereof
CN107106677A (zh) * 2014-08-28 2017-08-29 莱顿大学学术医院以Lumc的名义运作 Cd94/nkg2a和/或cd94/nkg2b抗体、疫苗组合
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
HK1255141A1 (zh) 2015-09-17 2019-08-09 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
US20180067121A1 (en) * 2016-09-06 2018-03-08 Nanoco Technologies Ltd. Exosome-conjugated quantum dot nanoparticles and methods of detecting exosomes and cancer using same
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
JP6990522B2 (ja) * 2017-04-11 2022-02-03 シスメックス株式会社 免疫細胞の免疫刺激応答性を測定する方法、免疫細胞における免疫シナプスの形成能を判定する方法及び細胞分析装置
CN108051581A (zh) * 2017-12-18 2018-05-18 河北中医学院 非共价键连接法半抗原---载体免疫原的制备
CN120154716A (zh) 2018-01-22 2025-06-17 恩多塞特公司 Car t细胞的使用方法
JP7774961B2 (ja) 2018-02-06 2025-11-25 シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート フルオレセイン結合エーテルリン脂質（ｆｌ－ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
JP7604397B2 (ja) 2019-05-20 2024-12-23 エンドサイト・インコーポレイテッド Ｐｓｍａコンジュゲートの調製方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1044781C (zh) * 1994-02-05 1999-08-25 丹东市生物制品免疫技术应用研究中心 复方免疫抗生素

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2816110A (en) * 1956-11-23 1957-12-10 Merck & Co Inc Methods for the production of substituted pteridines
US4314988A (en) 1979-10-31 1982-02-09 Baker Instruments Corp. Folic acid derivatives and process for preparation
US4713249A (en) * 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
US4659655A (en) * 1981-11-25 1987-04-21 Bio-Response, Inc. Method for isolating product-producing cells
US5140104A (en) * 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
ATE25197T1 (de) 1982-05-12 1987-02-15 Harvard College Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung.
NL8401226A (nl) 1984-04-16 1985-11-18 Univ Utrecht Farmaceutisch produkt met anti-tumorwerking; gebruik van een farmaceutisch produkt of van farmaceutische samenstellingen in een anti-tumortherapie.
EP0180171B1 (en) 1984-10-31 1992-04-08 Massachusetts Institute Of Technology Process for making a targeted cell susceptible to lysis by cytotoxic t lymphocytes
US5266333A (en) * 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US4681760A (en) 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
CA1282069C (en) * 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
NZ217821A (en) 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US5117022A (en) * 1985-10-18 1992-05-26 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
JPS6479125A (en) 1986-08-13 1989-03-24 Takeda Chemical Industries Ltd Antitumor agent
GB8626413D0 (en) 1986-11-05 1986-12-03 Gilliland L K Antibodies
US5888512A (en) 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
US4971792A (en) 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US4946945A (en) 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
PH26813A (en) 1987-09-02 1992-11-05 Ciba Geigy Ag Conjugates of cytokines with immunoglobulins
DK8189A (da) 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
GB8803365D0 (en) 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
EP0334300A1 (en) 1988-03-21 1989-09-27 Neorx Corporation The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites
DE3825615A1 (de) 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
EP0369387B1 (en) 1988-11-14 1996-05-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Spherical vinyl chloride resin granules and process for producing the same
JPH02169521A (ja) 1988-12-22 1990-06-29 Ajinomoto Co Inc 自己免疫疾患治療剤
DK0460076T3 (da) 1989-02-24 1996-03-25 Univ California Genetisk manipulerede immunoglobuliner
US5075287A (en) 1989-03-03 1991-12-24 Nisshin Oil Mills, Inc. Muramyl peptide derivatives and immunoregulating compositions containing them
GB8907310D0 (en) 1989-03-31 1989-05-17 Medical Res Council Heteroconjugates
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5217881A (en) 1989-04-25 1993-06-08 Immunex Corporation Hyperglycosylated cytokine conjugates
WO1991001004A1 (en) 1989-07-06 1991-01-24 Seragen, Inc. Hybrid molecules
KR920703114A (ko) 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
JP2807831B2 (ja) 1989-07-18 1998-10-08 国際試薬株式会社 免疫学的測定法
JPH0686375B2 (ja) 1989-09-25 1994-11-02 大塚製薬株式会社 リポソーム製剤
AU634314B2 (en) 1989-11-13 1993-02-18 Green Cross Corporation, The Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
DE69132925T2 (de) 1990-08-29 2002-10-10 Centre Hospitalier Regional De Nantes, Nantes An stabile proteinkernstruktur gebundene proteinpolyliganden
JP3105629B2 (ja) 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
IT1244983B (it) 1991-04-29 1994-09-13 Raggio Italgene Spa Procedimento per rivelare sequenze di acidi nucleici e kit per la sua utilizzazione.
JP3173814B2 (ja) 1991-05-30 2001-06-04 株式会社タムラ製作所 フラックス塗布方法
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5159079A (en) * 1991-12-20 1992-10-27 Eli Lilly And Company 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids
US5650398A (en) 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
ES2096215T3 (es) 1992-10-01 1997-03-01 Wellcome Found Tucaresol como agente inmunopotenciador.
DE4238416A1 (de) 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
DE69431620T2 (de) 1993-03-19 2003-07-03 Vacsyn S.A., Paris Zusammensetzungen für die anwendung in menschlicher therapie, charakterisiert durch die assoziation eines muramylpeptids mit einem cytokin
US5482698A (en) 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
ES2211882T3 (es) 1993-07-14 2004-07-16 The Regents Of The University Of California Sistema de cesion de polinucleotido, automontable que comprende policationes de dendrimeros.
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
JP2660661B2 (ja) 1994-05-11 1997-10-08 株式会社バイオセンサー研究所 遺伝子の定量方法
AU2705795A (en) 1994-06-16 1996-01-05 Board Of Trustees Of The Leland Stanford Junior University Immune modulation with class ii alpha-chain fragments
US5547668A (en) * 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
US5753625A (en) 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease
US5602171A (en) * 1995-06-07 1997-02-11 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof
AU1823697A (en) 1996-01-02 1997-07-28 Board Of Trustees Of The Leland Stanford Junior University Interaction of hla proteins with members of the hsp70 family of proteins
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
AU2610097A (en) 1996-04-10 1997-10-29 Sangstat Medical Corporation Cytomodulating conjugates of members of specific binding pairs
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
BR9809149A (pt) 1997-05-20 2000-08-01 Galenica Pharmaceuticals Inc Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
WO1999020626A1 (en) * 1997-10-17 1999-04-29 Purdue Research Foundation Folic acid derivatives
DE19746173A1 (de) * 1997-10-18 1999-04-22 Boehringer Ingelheim Int Tumorvakzine
AU5565599A (en) 1998-08-14 2000-03-06 Dante J. Marciani Chemically modified saponins and the use thereof as adjuvants
JP2004505885A (ja) * 1998-08-19 2004-02-26 ノース　アメリカン　ワクチン，　インコーポレイテッド Ｎ−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
WO2001032207A1 (en) * 1998-10-30 2001-05-10 United States Army Medical Research And Materiel Command Methods for conferring active/passive immunotherapy
AUPQ071299A0 (en) 1999-06-02 1999-06-24 Access Pharmaceuticals Australia Pty Limited Vitamin directed dual targeting therapy
CA2380888A1 (en) 1999-08-17 2001-02-22 Purdue Research Foundation Treatment of metastatic disease
JP4948728B2 (ja) 1999-08-17 2012-06-06 パーデュー・リサーチ・ファウンデーション 癌診断用抗体
AU7123500A (en) 1999-09-08 2001-07-09 Sloan-Kettering Institute For Cancer Research Polysialic acid-klh conjugate vaccine
SK287400B6 (sk) 1999-09-25 2010-08-09 University Of Iowa Research Foundation Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
AU783118B2 (en) 1999-09-27 2005-09-29 Coley Pharmaceutical Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
US20020039583A1 (en) 1999-09-30 2002-04-04 Subjeck John R. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
JP2003527352A (ja) 2000-01-13 2003-09-16 アンティジェニクス インコーポレーテッド Ｃｐｇおよびサポニンの自然免疫刺激化合物、ならびにそれらの方法
AU2001256970C1 (en) 2000-03-31 2008-07-03 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
CA2461877A1 (en) 2001-09-28 2003-04-10 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
CN1662251B (zh) 2002-04-19 2012-10-10 恩多塞特公司 佐剂增强的免疫应用
AR042942A1 (es) 2003-01-27 2005-07-06 Endocyte Inc Conjugados de administracion de drogas de union de receptores de vitaminas
US20050222068A1 (en) 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1044781C (zh) * 1994-02-05 1999-08-25 丹东市生物制品免疫技术应用研究中心 复方免疫抗生素

Also Published As

Publication number Publication date
US7033594B2 (en) 2006-04-25
KR20020087431A (ko) 2002-11-22
NZ521898A (en) 2004-11-26
HRP20020787A2 (en) 2004-02-29
CN1441676A (zh) 2003-09-10
SK13962002A3 (sk) 2004-02-03
AU5697001A (en) 2001-10-15
NO332160B1 (no) 2012-07-09
IL151927A0 (en) 2003-04-10
US8105608B2 (en) 2012-01-31
US20010031252A1 (en) 2001-10-18
EP1267918A1 (en) 2003-01-02
EP1267918A4 (en) 2007-06-27
NO20024577D0 (no) 2002-09-24
US20060067946A1 (en) 2006-03-30
WO2001074382A9 (en) 2002-10-10
AU2001256970C1 (en) 2008-07-03
KR100863632B1 (ko) 2008-10-15
PL357943A1 (en) 2004-08-09
NO20024577L (no) 2002-11-05
JP2003528924A (ja) 2003-09-30
CN102805868A (zh) 2012-12-05
PL211872B1 (pl) 2012-07-31
MXPA02009454A (es) 2003-04-10
SK288201B6 (sk) 2014-06-03
BR0109704A (pt) 2003-04-29
JP5059271B2 (ja) 2012-10-24
CA2405299C (en) 2014-07-22
HUP0300421A2 (hu) 2003-06-28
EA005823B1 (ru) 2005-06-30
WO2001074382A1 (en) 2001-10-11
IL213240A0 (en) 2011-07-31
CA2405299A1 (en) 2001-10-11
JP5632813B2 (ja) 2014-11-26
AU2001256970B2 (en) 2007-06-14
CZ20023240A3 (cs) 2003-10-15
CZ304942B6 (cs) 2015-02-04
DZ3332A1 (fr) 2001-10-11
IL213240A (en) 2015-04-30
HRP20020787B1 (hr) 2012-06-30
JP2012092097A (ja) 2012-05-17
EA200201042A1 (ru) 2003-04-24

Similar Documents

Publication Publication Date Title
CN1441676B (zh) 用配体-免疫原缀合物治疗的方法
AU2001256970A1 (en) Method of treatment using ligand-immunogen conjugates
AU2003224989B2 (en) Adjuvant enhanced immunotherapy
US20030086900A1 (en) Method of treatment using ligand-immunogen conjugates
ZA200207768B (en) Method of treatment using ligand-immunogen conjugates.
HK1179518A (en) Method of treatment using ligand-immunogen conjugates
AU2002353785A1 (en) Method of Treatment Using Ligand-Immunogen Conjugates

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120822

Termination date: 20150330

EXPY Termination of patent right or utility model